Quick Takeaways
- VANGUARD GROUP INC filed SCHEDULE 13G for Soleno Therapeutics Inc Common Stock (SLNO).
- Disclosed ownership: 5.3%.
- Date of event: 30 Sep 2025.
VANGUARD GROUP INC - 30 Sep 2025 SCHEDULE 13G Report for Soleno Therapeutics Inc Common Stock (SLNO)
- Filing Manager
- VANGUARD GROUP INC
- Reporting Manager
- The Vanguard Group
- Security
- Soleno Therapeutics Inc Common Stock
- Symbol
- SLNO
- Shares outstanding
- 53,165,701 shares
- Disclosed Ownership
- 2,807,149 shares
- Ownership
- 5.3%
- Form type
- SCHEDULE 13G
- Filing time
- 31 Oct 2025, 11:31:25 UTC
- Date of event
- 30 Sep 2025
- Next filing
- 27 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"VANGUARD GROUP INC disclosed 5.3% ownership in Soleno Therapeutics Inc Common Stock (SLNO) on 30 Sep 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 31 Oct 2025, 11:31.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| The Vanguard Group | 5.3% | 2,807,149 | 0 | 323,949 | Ashley Grim | Head of Global Fund Administration |